Navigation Links
Group of anti-diabetic drugs can significantly lower cancer risk in women with type 2 diabetes
Date:12/5/2013

Thursday, Dec. 5, 2013, Cleveland: A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

People with type 2 diabetes have a higher rate of cancer development and recurrence compared to the general population. This study published online today by the journal Diabetes, Obesity and Metabolism shows that widely prescribed anti-diabetes drugs can be linked to either an increased or decreased risk of cancer, depending on the type of medication prescribed.

A team of researchers led by Sangeeta Kashyap, M.D., an endocrinologist and associate professor of medicine at Cleveland Clinic's Endocrinology & Metabolism Institute, compared two groups of drugs commonly used to treat type 2 diabetes insulin sensitizers and insulin secretagogues. Insulin sensitizers lower blood sugar and insulin levels in the body by increasing the muscle, fat and liver's response to insulin. Insulin secretagogues lower blood sugar by stimulating pancreatic beta cells to make more insulin.

"What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes," said Kashyap. "By contrast, insulin sensitizers cut insulin levels and can decrease cancer growth. So, clearly, when prescribing anti-diabetic medications, it's important to consider the impact a drug has on fueling cancer growth."

In a retrospective analysis, researchers cross-indexed the electronic health record-based Cleveland Clinic Diabetes Registry (25,613 patients) with the histology-based tumor registry (48,051 cancer occurrences) over an 8-year period (19982006). More than 890 incident cancer cases were identified. The two most common cancers were prostate and breast, accounting for more than 25 percent of total cancer cases.

Study results show that the use of insulin sensitizers in female patients with type 2 diabetes was associated with a 21 percent decreased cancer risk compared with insulin secretagogues. Furthermore, the use of a specific insulin sensitizer, thiazolidinedione, was associated with a 32 percent decreased cancer risk in female patients compared with sulphonylurea, an insulin secretagogue. Results showed no significant difference in men.

The findings in this study contribute to existing research in the field on diabetic patients and their increased cancer risk. Further research is needed to examine the impact of oral diabetes therapy on cancer risk and development.


'/>"/>

Contact: Caroline Auger
augerc@ccf.org
216-636-5874
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. From herd immunity and complacency to group panic: How vaccine scares unfold
3. Study finds significant skull differences between closely linked groups
4. Diabetes Groups Issue New Guidelines on Blood Sugar
5. Small neural focus groups predict anti-smoking ad success
6. Group B streptococcal meningitis has long-term effects on childrens developmental outcomes
7. The Attilio Group’s TAG™-Simply Faster Taps SmartSales To Accelerate Its Expansion Into National Reach
8. Infants cant distinguish between large and small groups
9. Rush joins elite group of institutions with accredited research programs
10. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
11. Artisan Business Group hosts EB-5 Conference in California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... ... February 14, 2016 , ... In honor of ... Nurses (AAHFN) is promoting healthier living with heart failure by providing educational materials ... Living with Heart Failure will kick-off February 14 and includes tips on keeping ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy lifestyle ... reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those giving ... high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams of ...
(Date:2/13/2016)... ... ... an Au Pair comes all the way around the world to provide child ... are often worried things won’t go well. More often than not, however, they find out ... the Year winner’s all commented how their Au Pairs have become a part of the ...
(Date:2/12/2016)... ... 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett is ... these scholarships is to encourage applicants to pursue a degree in their field of ... parishes. , “We have available jobs in St. Landry and Evangeline Parishes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , 12 februari 2016 ... een toonaangevende leverancier van productie en ontwikkeling ... industrieën, kondigt vandaag een uitbreiding aan van ... haar locatie in Charleston, SC ... geleid tot meerdere recente investeringen. ...
(Date:2/12/2016)... , Ungarn, February 12, 2016 ... das sich auf den ungedeckten medizinischen Bedarf ... positive Ergebnisse seines klinischen Forschungsprogramms bekannt. Das ... beschäftigt, ergab Verbesserungen ihrer respiratorischen Funktionen und ... ltd , ein Medizintechnikunternehmen, das sich auf ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 ... - Companion Diagnostics in Personalized Medicine and Cancer ... Markets. - High-Growth Diagnostic Testing Markets. - ... Cancer Testing. - Molecular Diagnostics in Genetic Testing. ... - Molecular Diagnostics Markets. - Over-the-Counter Diagnostic Products ...
Breaking Medicine Technology: